Fujifilm to Acquire Biogen’s Danish Biologics Manufacturing Facility for $890M

 Fujifilm to Acquire Biogen’s Danish Biologics Manufacturing Facility for $890M

Fujifilm to Acquire Biogen’s Danish Biologics Manufacturing Facility for $890M

Shots:

  • Fujifilm acquires Biogen’s subsidiary having the production capacity of 90,000L biologics, in all-stock transaction for $890M. The acquisition is expected to be complete in H2’19
  • The focus of an acquisition is to expand Fujifilm’s bio CDMO business. It will provide Biogen a tax relaxation. As a part of the transaction Biogen also signs a service agreement with Fujifilm to develop products for Biogen including Tysabri
  • Biogen to develop a new manufacturing facility in Solothurn, Switzerland by H2’20 after the closing of this transaction

Click here to read full press release/ article | Ref: Biogen | Image: Biz Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post